Litcius/Paper detail

LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

D. J. Renouf, Jennifer J. Knox, Petr Kavan, Derek J. Jonker, Stephen Welch, Félix Couture, Frédéric Lemay, Mustapha Tehfé, Mohammed Harb, Nathalie Aucoin, Y-J. Ko, Patricia A. Tang, Ravi Ramjeesingh, Brandon M. Meyers, C. Kim, David F. Schaeffer, Jonathan M. Loree, Sharlene Gill, D. Tu, C. O'Callaghan

2020Annals of Oncology40 citationsDOI

Topics & Concepts

MedicineGemcitabineClinical endpointInternal medicineHazard ratioDurvalumabRandomized controlled trialOncologyNab-paclitaxelSurrogate endpointUrologyCancerGastroenterologyConfidence intervalImmunotherapyNivolumabCancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology ResearchPeptidase Inhibition and Analysis
LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC) | Litcius